Iron supplementation associates with low mortality in pre-dialyzed advanced chronic kidney disease patients receiving erythropoiesis-stimulating agents: A nationwide database analysis

Nephrology Dialysis Transplantation

Volumn 30, Issue 9, 2015, Pages 1518-1525

  Kuo, Ko Lin ^a,b   Hung, Szu Chun ^a,b   Liu, Jia Sin ^c   Chang, Yu Kang ^c   Hsu, Chih Cheng ^c,d   Tarng, Der Cherng ^e,f  

^a Buddhist Tzu Chi Medical Foundation   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Chronic kidney disease; dialysis; erythropoiesisstimulating agent; iron supplementation

Indexed keywords

ANTIANEMIC AGENT; CREATININE; IRON; FERRYL IRON;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIALYSIS; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FOLLOW UP; HEMATOCRIT; HIGH RISK POPULATION; HUMAN; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY ANALYSIS; SURVIVAL RATE; SYNDROME DELINEATION; VERY ELDERLY; YOUNG ADULT; CASE CONTROL STUDY; COMPARATIVE STUDY; DIET SUPPLEMENTATION; DISEASE COURSE; FACTUAL DATABASE; INTRAVENOUS DRUG ADMINISTRATION; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; STATISTICS; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; FEMALE; HEMATINICS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; STATISTICS AS TOPIC; SURVIVAL RATE; TAIWAN; YOUNG ADULT;

EID: 84940647535     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv085     Document Type: Article

References (37)

1. Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189
2. Hörl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: 382-393
3. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538
4. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076
5. Kuo KL, Hung SC, Lee TS et al. Iron sucrose accelerates early atherogenesis by increasing superoxide production and upregulating adhesion molecules in CKD. J Am Soc Nephrol 2014; 25: 2596-2606
6. Salahudeen AK, Oliver B, Bower JD et al. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001; 60: 1525-1531
7. Tovbin D, Mazor D, Vorobiov M et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002; 40: 1005-1012
8. Guz G, Glorieux GL, De Smet R et al. Impact of iron sucrose therapy on leukocyte surface molecules and reactive oxygen species in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 2834-2840
9. Kuo KL, Hung SC, Wei YH et al. Intravenous iron exacerbates oxidative DNAdamage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19: 1817-1826
10. Kuo KL, Hung SC, Lin YP et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS ONE 2012; 7: e50295
11. Druëke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
12. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J AmSoc Nephrol 2005; 16: 3070-3080
13. Hoen B, Kessler M, Hestin D et al. Risk factors for bacterial infections in chronic haemodialysis adult patients: a multicentre prospective survey. Nephrol Dial Transplant 1995; 10: 377-381
14. Boelaert JR, Daneels RF, Matthys EG et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. Nephrol Dial Transplant 1990; 5: 130-134
15. Feldman HI, Santanna J, GuoWet al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
16. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632
17. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff. (Millwood) 2003; 22: 61-76
18. Hsu TW, Liu JS, Hung SC et al. Renoprotective effect of renin-angiotensinaldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension and anemia. JAMA Intern Med 2014; 174: 347-354
19. Hwang SJ, Yang WC, Lin MY et al. Impact of the clinical conditions at dialysis initiation onmortality in incident haemodialysis patients: a national cohort study in Taiwan. Nephrol Dial Transplant 2010; 25: 2616-2624
20. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383
21. Tsan YT, Lee CH, Wang JD et al. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol 2012; 30: 623-630
22. Lunceford JK, Davidian M. Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study. Stat Med 2014; 23: 2937-2960
23. Iezzoni LI. Risk Adjustment for Measuring Health Care Outcomes. Ann Arbor, MI: Health Administration Press, 1997
24. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
25. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
26. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000
27. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084
28. Streja E, Kovesdy CP, Greenland S et al. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008; 52: 727-736
29. Pollak VE, Lorch JA, Shukla R et al. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 2009; 10: 6
30. Zager RA, Johnson AC, Hanson SY et al. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103
31. Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004; 66: 144-156
32. Agarwal R, Vasavada N, Sachs NG et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289
33. Agarwal R, Rizkala AR, Kaskas MO et al. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease. Kidney Int 2007; 72: 638-642
34. Agarwal R, Leehey DJ, Olsen SM et al. Proteinuria induced by parenteral iron in chronic kidney disease-A comparative randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 114-121
35. Kovesdy CP, Estrada W, Ahmadzadeh S et al. Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 435-441
36. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886
37. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892